“双引擎”平台破局新药研发,百奥赛图“A+H”上市与盈利双突破背后的逻辑

市值风云
Dec 10, 2025

全球前十药企都在买的两张“地图”。作者 |观韬编辑 |小白药效上不去,毒性下不来——这恐怕是每一个抗体新药研发者最深的梦魇。投入数年、耗费亿万,最终在临床试验中黯然离场的项目,问题究竟出在哪?实践表明,绝大多数失败,都源于最初的双重错配。一是候选抗体分子与人体复杂环境的错配,二是临床前动物模型与真实疾病机制的错配。这就像用一张错误的地图去寻宝,出发的那一刻,结局已然注定。成功的抗体药物研发,本质上...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10